models are being contemplated. Rapid translation of immunoncology agents to the clinic will require standardization of immunologic assay lkthods and a more detailed immunologic characterization of common mouse models. Outlined here are the critical elelknts in assessing immunity in cancer mouse models and suggestions concerning the
models are being contemplated. Rapid translation of immunoncology agents to the clinic will require standardization of immunologic assay lkthods and a more detailed immunologic characterization of common mouse models. Outlined here are the critical elelknts in assessing immunity in cancer mouse models and suggestions concerning the